<p>Opus Genetics Inc. will participate in several upcoming medical and industry conferences in February 2026. The company’s leadership will join discussions at the Collaborative Community on Ophthalmic Innovation (CCOI) and the Asia-Pacific Academy of Ophthalmology Congress (APAO), both taking place in Hong Kong from February 3-8, 2026. Additionally, Opus Genetics’ Chief Technology Officer, Chris Ernst, will speak at the Advanced Therapies Week Conference in San Diego, CA, on February 11, 2026. The company will also present preliminary results from a clinical study at the Macula Society Annual Meeting in San Diego, CA, on February 27, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9645909-en) on February 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

IBBQ

SBIO

<p>Opus Genetics Inc. will present preliminary results of its OPGx-BEST1 gene therapy at the Macula Society Annual Meeting on February 27, 2026. The company will also participate in several conferences, including the Collaborative Community on Ophthalmic Innovation and the Asia-Pacific Academy of Ophthalmology Congress in Hong Kong from February 3-8, 2026, and the Advanced Therapies Week Conference in San Diego on February 11, 2026.</p>

Reuters

First Trust NYSE Arca Biotech Index Fd

Opus Genetics

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

VanEck Biotech ETF

ALPS Medical Breakthrough

Opus Genetics to Present Preliminary Results of OPGx-BEST1 Gene Therapy at Macula Society Annual Meeting